Senolytics

Senolytics are a class of therapeutic agents designed to selectively eliminate senescent cells by disabling their pro-survival networks [1, 5, 7]. The scientific consensus establishes that senescent cells accumulate with age and at causal sites of multiple chronic, age-related disorders, contributing to inflammation and tissue dysfunction via the senescence-associated secretory phenotype (SASP) [5, 7, 8]. Preclinical evidence demonstrates that clearing these cells using genetic models or small-molecule combinations (such as Dasatinib plus Quercetin) enhances healthspan, improves physical function, and increases lifespan in mice [1, 2, 6]. Furthermore, preliminary human trials indicate that senolytics can be deployed to decrease senescent cell burdens in conditions like diabetic kidney disease and idiopathic pulmonary fibrosis [5, 6].

Open questions remain regarding the precise translational efficacy, long-term safety profiles, and optimal dosing regimens of senolytic therapies in diverse human populations [5, 6]. While acute induction of cellular senescence can be protective against cancer and limit fibrosis, the chronic persistence of these cells drives pathology, necessitating carefully timed interventions [8].